Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Published:2017-07-05 Issue:2 Volume:32 Page:391-401
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Besse A,Stolze S C,Rasche L,Weinhold N,Morgan G J,Kraus M,Bader J,Overkleeft H S,Besse L,Driessen C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017212.pdf

Reference60 articles.

1. Rajkumar SV, Kumar S . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101–119.

2. Lu S, Wang J . The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 2013; 1: 13.

3. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S . Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014; 18: 947–961.

4. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27–38.

5. Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014; 124: 63–69.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug resistance in human cancers — Mechanisms and implications;Life Sciences;2024-09

2. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction;International Journal of Molecular Sciences;2024-08-16

3. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer;British Journal of Cancer;2024-07-05

4. Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma;2024-05-31

5. Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple Myeloma;2024-04-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3